Search clinical trials for: novolog

Total 105 results

Second Affiliated Hospital, School of Medicine,...

Recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Time in Range | HbA1c | Type 1 Diabetes Mellitus With Diabetic Gastroparesis

China
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
Emory University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Oral Anti Diabetic Agents in the Hospital

Diabetes Mellitus

United States
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaborators

Active, not recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Germany, France, Australia
Sanofi

Completed

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (GEMELLI X)

Type 1 Diabetes Mellitus

United States
Boston Medical Center
Novo Nordisk A/S

Completed

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (In-FI)

Type 2 Diabetes Treated With Insulin

United States
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Amphastar Pharmaceuticals, Inc.

Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Pharmacokinetics | Pharmacodynamics

United States
University at Buffalo

Completed

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
The Cleveland Clinic
Novo Nordisk A/S

Completed

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D)

Type 2 Diabetes

United States
Emory University

Completed

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Spectrum Health Hospitals
Helen DeVos Children's Hospital

Completed

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

Type 1 Diabetes Mellitus

United States
Emory University
Novo Nordisk A/S

Completed

IDegLira HIGH Trial

Diabetes Mellitus

United States
Rush University Medical Center

Terminated

Carbohydrate Consumption as a Factor in Aspart Dosing (CARB)

Diabetes

United States
Massachusetts General Hospital
Boston University

Terminated

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

Type 1 Diabetes Mellitus

United States
Arecor Limited

Completed

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Diabetes Mellitus, Type 1

United States
University of Minnesota

Completed

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Cystic Fibrosis

United States
Sanofi

Completed

Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes

Germany
Sanofi

Completed

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (SWITCH)

Type 2 Diabetes Mellitus

China
Sanofi

Completed

A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes

Germany
Sanofi

Terminated

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Type 1 Diabetes Mellitus

United States, Canada
Emory University
Novo Nordisk A/S

Completed

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Sanofi

Completed

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (GEMELLI1)

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

Hungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Mylan Inc.
Mylan GmbH

Completed

Mylan Insulin Aspart Study

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Albert Einstein College of Medicine
National Institute on Aging (NIA)

Completed

Cardiac Surgery Neuroprotection Study in Elders (CNS-Elders)

Post-operative Delirium | Post-operative Cognitive Decline

United States
Stanford University
Medtronic

Completed

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Diabetes Mellitus, Type 1

United States
Albert Einstein College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

New Onset Type 1 Diabetes: Role of Exenatide

Type 1 Diabetes

United States
Arecor Limited

Completed

AT278 and NovoRapid® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
Michigan State University

Completed

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

Exercise | Insulin

United States
Mountain Diabetes and Endocrine Center

Completed

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

Diabetes Mellitus, Type II

United States
Tulane University Health Sciences Center

Completed

Comparison of Insulins Aspart and Lispro in Insulin Pumps

Type 1 Diabetes Mellitus

United States
Mountain Diabetes and Endocrine Center

Unknown

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus (PLATEAU)

Type 1 Diabetes Mellitus

United States
Texas Diabetes & Endocrinology, P.A.

Completed

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Type 1 Diabetes Mellitus

United States
Northwestern University

Terminated

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Insulin Resistance, Diabetes | Hyperglycemia Steroid-induced

United States
University of Milan
Azienda Farmaceutica Italiana s.r.l.

Unknown

Efficacy of Zinc L-Carnosine Mouth Rinse

Pain | Periodontal Index

Italy
Wake Forest University Health Sciences
National Institute on Aging (NIA); General Electric

Completed

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (SNIFF-Quick)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Dennis G. Karounos, M.D.
Novo Nordisk A/S

Completed

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy (VIISTA)

Type 2 Diabetes Mellitus

United States
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males

Diabetes Mellitus, Type 1

Germany
Massachusetts General Hospital

Completed

The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study

Type1 Diabetes Mellitus

United States
Emory University

Completed

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (SITA-CABGDM)

Hyperglycemia

United States
Arecor Limited

Completed

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
Massachusetts General Hospital

Completed

The Insulin-Only Bionic Pancreas Bridging Study

Type1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Type 1 Diabetes Mellitus

United States
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
University of Texas Southwestern Medical Center
Novo Nordisk A/S

Withdrawn

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin (RASCIN)

Type 2 Diabetes

United States
Halozyme Therapeutics

Completed

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Terminated

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma (iINHALE 9)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Asthma

United States, Slovakia, India, Malaysia, Australia, Former Serbia and Montenegro

Search clinical trials for: novolog

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations